Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World January 21, 2010 Rebecca Renner	FDA shifts on BPA safety The US Food and Drug Administration has revised its position on the possible developmental health risks from bisphenol A, the controversial and widely used ingredient in hard plastic bottles and food packaging that it declared safe in 2008.
Chemistry World September 8, 2008 Rebecca Trager	NIH reaffirms BPA concerns The US National Institutes of Health has again expressed 'some concern' about the effects of bisphenol A on the brain, behavior, and prostate gland in fetuses, babies, and children at current exposure level
Pharmaceutical Executive February 1, 2011 Jill Wechsler	The Building Block of Drug Discovery With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
Chemistry World November 4, 2008 Rebecca Trager	FDA criticised by its own experts over bisphenol A The US Food and Drug Administration (FDA)'s recent conclusion that controversial chemical bisphenol A (BPA) is safe at current levels is flawed, the agency's own Science Board has warned.
IndustryWeek October 19, 2011	FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies?
Chemistry World November 11, 2008 Rebecca Trager	Chemical industry cautious about Obama presidency The chemical industry's guarded response to the election of Democrat Barack Obama as the 44th US president stands in stark contrast to the enthusiastic reception he received from chemists.
Chemistry World December 19, 2011 Rebecca Trager	US agencies collaborate to test 10,000 chemicals A high-speed robotic screening system jointly initiated by three key US health agencies began testing more than 10,000 chemical compounds for potential toxicity on 7 December.
Pharmaceutical Executive January 1, 2009 Jill Wechsler	FDA Turnaround Time Will more resources and new leadership fix FDA, or is a major overhaul in order?
Investment Advisor June 2010 Melanie Waddell	The Regulators Never Sleep The SEC and the CFTC have formed a joint committee that will address emerging regulatory issues.
Pharmaceutical Executive June 1, 2012 Jill Wechsler	Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
Pharmaceutical Executive January 1, 2006 Clinton & Wechsler	What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay?
Chemistry World April 18, 2008 Rebecca Trager	Canada may brand bisphenol A 'toxic' Canada's national public health agency looks set to become the first regulator in the world to label Bisphenol A (BPA) -- used for decades in products like plastic baby bottles and food containers -- 'toxic' and 'hazardous'.
Chemistry World February 7, 2013 Rebecca Trager	Small business office chemical industry pawn, watchdog claims The activities of the Office of Advocacy -- an independent office charged with protecting the interests of small businesses with a budget of just over $9 million -- have been examined by the Center for Effective Government, a Washington, DC watchdog.
Pharmaceutical Executive December 1, 2010 Ansis Helmanis	A New Twist in the Cost Curve The strict regulatory divide between market authorization and price reimbursement is crumbling in the US. Is industry prepared to adapt or challenge?
InternetNews July 27, 2010	FDA, FCC Push For Wireless Health Technology The government agencies are teaming up to use the latest and greatest wireless technology to improve care and reduce healthcare costs using electronic health records.
Pharmaceutical Executive January 1, 2007 Jill Wechsler	Washington Report: A Full Plate It's going to be a busy year in Washington for the pharmaceutical industry. Drug safety, unapproved uses, e-data requirements, and a shift to personalized medicine are just a few of the hot issues on tap for 2007.
Chemistry World February 18, 2009 Rebecca Trager	Obama Signs Off on Billions of Dollars for Research US president Barack Obama has signed into law a massive economic stimulus bill that contains an extra $21.5 billion ( 15 billion) in federal research and development support, impressing the scientific community.
Pharmaceutical Executive October 1, 2005 Alana Klein	Ad Agencies to the Rescue Faced with strict guidelines and regulatory pressures over advertising, pharmaceutical clients are looking to their agencies for support and guidance.
Scientific American January 2006	Saving Animals and People Use of animals in testing and in biomedical research continues to be necessary and is ethically preferable to experimenting on humans or forgoing cures that could save human lives, but the development and acceptance of animal substitutes deserve enthusiastic support.
Pharmaceutical Executive December 1, 2005 Jill Wechsler	Washington Report: Big Production Drug manufacturing costs too much and is cumbersome to regulate. FDA's answer: Quality by design, which shifts the emphasis from testing the final product to building quality into the manufacturing process from the beginning.
Chemistry World May 14, 2015 Rebecca Trager	California demands warning labels for BPA The US state of California has added bisphenol A to its Proposition 65 list of chemicals linked to health concerns, despite opposition from the chemical industry.
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World July 20, 2015 Rebecca Trager	US chemical industry lobby group in the hot seat again The American Chemistry Council has come under fire once again, just months after it was publicly accused of lying about having no involvement with a phony fire safety coalition.
Pharmaceutical Executive August 1, 2008 Jill Wechsler	Can Sentinel Save Drug Development? FDA's new sentinel system shows the pendulum swing toward safety won't swing back anytime soon.
Pharmaceutical Executive March 1, 2012 Ron Cohen	FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.
Chemistry World February 8, 2012 Rebecca Trager	Obama urged to cut FDA ties with Monsanto The petition specifically mentions Michael Taylor as a former vice president and lobbyist with the firm, and suggests that he should be removed from his position as the FDA's deputy commissioner for foods.
Chemistry World September 12, 2008 Rebecca Trager	NIH funds chemical biology network NIH-funded scientists will have access to the tools for rapidly screening hundreds of thousands of small molecules against many novel biological assays at lower costs than previously possible,' said the agency's director, Elias Zerhouni.
Chemistry World October 7, 2013 Andrew Williams	California takes on chemicals in consumer goods California has just introduced a new law to reduce the use of hazardous substances in products and industrial processes in the state.
Pharmaceutical Executive December 1, 2011 Jill Wechsler	FDA Gets a New Look Agency expansion and globalization promote innovation, collaboration, and organizational changes
Chemistry World February 5, 2008 Rebecca Trager	Bush Budget Proposal Backs Physical Sciences US President George Bush wants to get the budget for physical sciences research back on track, but biomedical research could suffer in his budget proposals for 2009.
Chemistry World April 24, 2008 James Mitchell Crow	FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches.
Bio-IT World March 8, 2005 Salvatore Salamone	Nano Poised for Liftoff First 'nano' technologies yield fruit in the biomedical lab and clinic with the promise of more to come.
Chemistry World October 4, 2013 Rebecca Trager	US government shutdown hits science, chemical industry Researchers working at American universities and agencies are reeling after the US government shutdown on 1 October. The chemical industry has not escaped the effects of the political spat either.
Bio-IT World January 21, 2005 Jim Golden	Top 10 Trends for 2005 Pharmacovigilance, compliance, outsourcing, and the CIO's role will be big this year.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	Guiding a Revolution in Science Francis Collins led the genomic revolution as director of the International Human Genome Project and director of the National Human Genome Research Institute (NHGRI) at the NIH from 1993 to 2008.
Pharmaceutical Executive March 1, 2007 Jill Wechsler	Washington Report: Safety First FDA seeks to regain public trust by making drug-safety information more transparent - and to head off more stringent legislation in the process.
Pharmaceutical Executive May 1, 2007 Weiner & Hovde	Critical Mass for Critical Path? Everyone agrees that it's the road to pharma's future, but no one's rushing to take it. Yet with growing FDA advocacy and new advances in biomarkers and drug-disease modeling, the rewards of collaboration now look greater than the risks.
Bio-IT World April 16, 2004	Best of the Best, Sir The FDA wants to change its ways and share its accumulated wisdom as part of a focused attack on costly, unpredictable product development.
Pharmaceutical Executive October 1, 2012 Jill Wechsler	Changes and Challenges at FDA New user fee programs precipitate major changes at an agency under constant and intense scrutiny.
Pharmaceutical Executive May 1, 2006 Jill Wechsler	Washington Report: Opportunity Knocks FDA has finally released its long-awaited list of research opportunities for the Critical Path initiative. Now comes the hard part, as companies learn how to collaborate on projects that will benefit pharma as a whole.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
Food Processing October 2008 Diane Toops	A Conversation with Food Safety Czar David W.K. Acheson A exclusive conversation with `food safety czar' David W.K. Acheson, FDA's Associate Commissioner for Foods.
Pharmaceutical Executive February 1, 2011 Jill Wechsler	Challenges, Changes, Commitments The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
Pharmaceutical Executive September 1, 2013 Jill Wechsler	Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies.
Chemistry World May 21, 2009 Rebecca Trager	FDA gets new chief The US Food and Drug Administration's (FDA) new commissioner, Margaret Hamburg, will be the second woman to ever lead FDA
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.
Chemistry World October 23, 2013 Sarah Houlton	Pharma manufacturing woes dog industry Many problems arise from quality control failures, according to Nicholson Price from Harvard Law School's Petrie-Flom center for health law policy, biotechnology and bioethics, this is not the only problem -- regulatory constraints can prevent process improvements being made.
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
The Motley Fool December 5, 2007 Brian Lawler	The FDA Says It Needs a Pep Pill Drugmakers offering new treatments might be discouraged by the FDA's latest report, in which the agency makes its case for additional funding from Congress.